Vancomycin prodrug 

Vancomycin prodrug (compound 13c) is a Vancomycin (HY-B0671) prodrug. Vancomycin prodrug shows antibacterial effect with MICs of 0.78 μM, 0.78 μM, 1.56 μM for S. aureus 330041, MRSA USA 300 and MRSA 3390, respectively. Vancomycin prodrug has the ability to quickly bind to Cys-34 residue of plasma. Vancomycin prodrug exhibits a good therapeutic effect on MRSA USA300 infected mice similar to Vancomycin. Vancomycin prodrug, an albumin-binding acid-sensitive prodrug, effectively reduces Vancomycin’s nephrotoxicity while maintaining its efficacy for Gram-positive bacterial infections^[1].

1805.63

C₈₅H₉₅Cl₂N₁₁O₂₉

CN[C@@H](C(N[C@H]1C(N[C@H](C(N[C@H]2C(N[C@H]3C(N[C@@H]([C@@H](C4=CC(Cl)=C(OC5=CC2=CC(OC6=CC=C([C@H]1O)C=C6Cl)=C5O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O[C@H]8C[C@](/N=C/C9=CC=C(C=C9O)OCC(NCCCCCCN%10C(C=CC%10=O)=O)=O)([C@@H]([C@@H](O8)C)O)C)O)O)CO)C=C4)O)C(N[C@@H](C%11=CC(O)=CC(O)=C%11C%12=C(C=CC3=C%12)O)C(O)=O)=O)=O)=O)=O)CC(N)=O)=O)=O)CC(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tao Li, et al. Targeted vancomycin delivery via in situ albumin conjugation and acid-triggered drug release for reduced nephrotoxicity. Eur J Med Chem. 2025 Jul 5:291:117652.